Tevogen Bio Holdings Inc. (“Company” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T-cell therapeutics for ...

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

K-Bio leaders pursue U.S. factories and conferences during Lunar New Year K-Bio executives opt for international business ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

ABL Bio, which is developing new drugs based on a dual antibody ... Lee said, “During a meeting held during the JP Morgan Healthcare Conference (JPM 2025) this month, global big pharmaceutical ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

After revenue boomed for biopharma manufacturers during the COVID pandemic, sales have stagnated for several CDMO giants, ...

Ascentage Pharma Group said its American depositary shares were slated to begin trading on the Nasdaq Global Market on Friday, with its initial public offering priced at $17.25 per ADS.

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

Thermo Fisher Scientific should be safe. RFK Jr. may disrupt Big Pharma, but he’s unlikely to cause research to completely ...

Morgan Stanley (NYSE:MS) updated its outlook on Kirin Holdings Co Ltd (2503:JP) (OTC: KNBWY), raising the company's price target from ¥2,200 to ¥2,250, while sustaining an Equalweight rating on the ...

JPMorgan Chase & Co. grew its position in shares of Bioceres Crop Solutions Corp. (NASDAQ:BIOX – Free Report) by 49.3% in the ...